Cynomolgus IGFBP-2 Protein

Cat. No. IGF-CM102



Description	
Source	Recombinant Cynomolgus IGFBP-2 Protein is expressed from HEK293 with His tag at the C-Terminus.
	It contains Gly33-Gln325.
Accession	A0A2K5WZA2
Molecular Weight	The protein has a predicted MW of 32.83 kDa. Due to glycosylation, the protein migrates to 35-45 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Insulin-like growth factor (IGF) binding protein 2 (IGFBP2) was discovered and identified as an IGF system regulator, controlling the distribution, function, and activity of IGFs in the pericellular space. IGFBP2 is a developmentally regulated gene that is highly expressed in embryonic and fetal tissues and markedly decreases after birth. Aberrant expression of IGFBP2 in cancer acts as a hub of an oncogenic network, integrating multiple cancer signaling pathways and serving as a potential therapeutic target for cancer treatment.


Assay Data

Bis-Tris PAGE



Cynomolgus IGFBP-2 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Cynomolgus IGFBP-2 is greater than 95% as determined by SEC-HPLC.